As the scientific community search for alternatives to broad spectrum antibiotics, phage therapy has re-emerged as a viable solution to tackle the global health challenge of anti-microbial resistance.
As such, the 2nd Bacteriophage Therapy Summit returns digitally as a dedicated platform for leaders in industry and academia to accelerate the discovery and translation of bacteriophage research into targeted therapeutics that demonstrate clinically significant results.
With a heavy translationally focused agenda including how to overcome bacterial resistance scaling-up manufacturing and showing clinical efficacy this is your opportunity to join your peers to strengthen your product development pipelines and forge collaborations to unlock the full potential of bacteriophage therapeutics.
View the full event guide for further details on speakers, content and how to join those who paving the way for bacteriophage-based therapeutics!
Conference Only - Industry: USD 1749.00,
Conference Only - Academic/Start-Up: USD 1249.00
Speakers: Greg Merril, Adaptive Phage Therapeutics, Duane Morris, Armata Pharmaceuticals, Carrie-Lynn Langlais Furr, Bacteria and Drug Development Consultants, Ales Strancar, BIA Separations, Chandrabali Ghose, Bioharmony Therapeutics, Sailaja Puttagunta, BiomX, Steven Theriault, Cytophage Technologies, Xavier Duportet, Eligo Bioscience, Eric Pelfrene, EMA, Rebecca Reindel, FDA, Scott Stibitz, FDA, Shawna McCallin, Hopitaux Universitaires de Genève, Daniel Stahm, International Health Management Associates, Tuval Ben-Yehezkel, Loop Genomics, Danish Malik, Loughborough University, Kevin Yehl, Massachusetts Institute of Technology, Conrad Lichtenstein, Nemesis Bioscience, Liesl Jeffers-Francis, North Carolina AandT State University, Nancy Tawil, Phagelux, Lorenzo Corsini, PhagoMed, James Cass, Phico Therapeutics, Jaroslaw Dastych, Proteon Pharmaceuticals, Vincent Fischetti, Rockefeller University, Paul Turner, Yale University